Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins
- PMID: 11227019
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins
Abstract
The use of plasmid DNA encoding influenza viral proteins to vaccinate animals constitutes a promising approach to the development of effective subunit vaccines. This review describes the results obtained by the immunization of mice with such plasmid DNAs. (i) Both hemagglutinin (HA)- and neuraminidase (NA)-expressing DNAs for the surface glycoproteins from A/PR/8/34 (H1N1) or B/Ibaraki/2/85 virus can provide the most effective protection against influenza A-type or B-type virus infection among the various viral protein-expressing DNAs tested in BALB/c mice. (ii) A mixture of plasmid DNAs encoding HA and NA can provide more effective protection against virus challenge than plasmid DNA encoding HA or NA alone in BALB/c mice. (iii) NA-DNA can provide protection against infection not only by homologous virus but also by drift viruses. (iv) HA-DNA from A/PR/8/34 (H1N1) virus provides significant protection only in BALB/c (H-2(b)) mice, whereas HA-DNA from B/Ibaraki/2/85 virus affords significant protection in BALB/c, B10 (H-2(d)), and C3H (H-2(k)) mice. NA-DNA from both A-type and B-type viruses provides significant protection in the three strains of mice. These results suggest that both HA and NA molecules should be used as vaccine components to provide effective protection against influenza A-type and B-type virus infection in genetically heterogeneous humans.
Similar articles
-
Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.Vaccine. 2005 Jul 29;23(34):4322-8. doi: 10.1016/j.vaccine.2005.03.035. Vaccine. 2005. PMID: 15925433
-
Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.Biochem Biophys Res Commun. 2006 May 19;343(4):1124-31. doi: 10.1016/j.bbrc.2006.03.088. Epub 2006 Mar 23. Biochem Biophys Res Commun. 2006. PMID: 16580631
-
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.Vaccine. 1999 Feb 26;17(7-8):653-9. doi: 10.1016/s0264-410x(98)00247-3. Vaccine. 1999. PMID: 10067670
-
Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.Jpn J Infect Dis. 2005 Aug;58(4):195-207. Jpn J Infect Dis. 2005. PMID: 16116250 Review.
-
Molecular studies on the diversification of hemagglutinin-specific human neonatal repertoire subsequent to immunization with naked DNA.Vaccine. 2004 Apr 16;22(13-14):1624-30. doi: 10.1016/j.vaccine.2003.10.045. Vaccine. 2004. PMID: 15068844 Review.
Cited by
-
Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes.Immunol Res. 2014 Oct;60(1):23-34. doi: 10.1007/s12026-014-8489-0. Immunol Res. 2014. PMID: 24515613
-
Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.J Virol. 2005 Aug;79(15):9854-61. doi: 10.1128/JVI.79.15.9854-9861.2005. J Virol. 2005. PMID: 16014946 Free PMC article.
-
Construction of recombinant fusion protein of influenza, a virus neuraminidase and heat shock protein 70 gene: expression in baculovirus and bioactivity.J Med Life. 2015;8(Spec Iss 4):189-195. J Med Life. 2015. PMID: 28316730 Free PMC article.
-
Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.NPJ Vaccines. 2025 Feb 11;10(1):28. doi: 10.1038/s41541-025-01086-0. NPJ Vaccines. 2025. PMID: 39934182 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials